Pramlintide acetate supplier API Pharmaceutical Polypeptide made in china 196078-30-5
AI Product Description
*The following content is generated by AI and is for reference only.
Pramlintide Acetate is a synthetic analog of human amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. Produced in China as a high-purity API (Active Pharmaceutical Ingredient) for pharmaceutical applications, it serves as a critical therapeutic agent in the management of diabetes mellitus. Its molecular formula is C90H136N24O27·xCH3COOH, reflecting its complex polypeptide structure coupled with acetate counterions to ensure stability and solubility. The CAS number for pramlintide acetate is 185207-06-5. This compound acts as an amylin receptor agonist, mimicking the physiological effects of native amylin to regulate glucose homeostasis.
The primary clinical use of Pramlintide Acetate is as an adjunct therapy for patients with type 1 or type 2 diabetes who require insulin but struggle with postprandial hyperglycemia and weight gain associated with intensive insulin regimens. By binding to specific receptors in the brainstem and pancreas, it delays gastric emptying, suppresses inappropriate glucagon secretion after meals, and enhances satiety signals. These mechanisms collectively reduce post-meal blood glucose spikes without increasing the risk of hypoglycemia when used correctly alongside mealtime insulin.
Manufactured in China using advanced solid-phase peptide synthesis techniques, this API meets stringent international quality standards, including GMP compliance. It is supplied to global pharmaceutical formulators for the production of injectable solutions and pre-filled pens. The product is characterized by high chemical purity, low endotoxin levels, and precise stereochemical configuration essential for biological activity. As obesity and diabetes prevalence rise globally, the demand for effective peptide-based therapeutics like pramlintide continues to grow. Chinese manufacturers have established robust supply chains capable of scaling production while maintaining rigorous quality control protocols. This ensures a reliable source of high-quality API for developing next-generation diabetes treatments. The drug represents a significant advancement in metabolic disease management, offering clinicians a valuable tool to optimize glycemic control and improve patient outcomes through a multi-mechanistic approach that addresses both insulin deficiency and dysregulated appetite.